Business Wire

Now Is the Time To Host Events in Japan, With the Yen at a Low! Global Produce Launches Full-Scale Production of “Event Hosting in Japan” for Overseas Companies

4.12.2024 16:00:00 CET | Business Wire | Press release

Share

Providing English support, potential venues such as arenas and historic buildings, and more—a team of event professionals bringing unique, extraordinary, and emotional events to life!

Global Produce Co., Ltd. (Head Office: Shibuya Ward, Tokyo; CEO: Masaki Kouhata; hereinafter referred to as “Global Produce”), a company specializing in event production, is pleased to announce the full-scale launch of its production services for overseas companies looking to host events in Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121186571/en/

Global Produce Launches Full-Scale Production of “Event Hosting in Japan” for Overseas Companies (Graphic: Business Wire)

With Global Produce, your dream event in Japan can become a reality!

Our “Japan Event Hosting Plan” was created to bring the visions of overseas companies to life using events hosted in Japan. Not only will native speakers be present at the forefront, but our producers, with over 30 years of experience, will accompany you every step of the way. They utilize their extensive expertise and innovative creativity, using the latest technologies to create extraordinary, emotionally impactful events. In addition to large venues such as Makuhari Messe and other arenas, we also collaborate with unique venues all across Japan. You can even host events at historic buildings and iconic locations. Start by sharing your ideas with us—we’ll offer diverse proposals to shape your vision into the most captivating experience possible.

Reasons behind the service’s creation

Reason 1 | Japan’s affordability on a global scale
With lower prices compared to other countries and weaker yen allowing for more purchasing power with foreign currencies, it’s clear that now is an advantageous time for spending money in Japan.

Reason 2 | Japan’s allure meets a language barrier
Determining event specifics requires not only technical terminology, but also an understanding of cultural nuances unique to individual countries, which can pose a challenge.

Reason 3 | Limited access to venues that truly highlight Japan’s appeal
Many overseas companies have expressed frustration at only being offered formal seminar-style venues when reaching out to Japan, finding it difficult to connect with more traditional and iconic locations.

Overview

Company: Global Produce Co., Ltd.
Headquarters: 5-52-2 Jingumae, Shibuya, Tokyo
Website: https://globalproduce-event.com
LinkedIn: https://www.linkedin.com/company/global-produce-2011/

View source version on businesswire.com: https://www.businesswire.com/news/home/20241121186571/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye